Ann: Immutep Appoints LAG-3 Pioneer Dr Frederic Triebel to Board, page-26

FT has 3.5 million performance rights due in 4 tranches
1st Oct 2022 through to 1st Oct 2025.
Vesting based on continuous employment and achievement of medical, regulatory, manufacturing, scientific AND "investor relations objectives to assist raising awareness"

Becoming an exec director gives him more clout on all fronts and I would think he will be wheeled out more often especially as Lag-3 becomes known worldwide.

it's a good move to promote FT to the board and should have been done years ago.

Clinical Update:-
Language has significantly shifted from historical reserved to more positive. For example

"Commercialisation" used by both RH/FT
"More frequent regulatory interactions",
"Potentially enables rolling review of biological license application"
"Maximising full treatment potential of efti"
"Accelerated approval and priority review" (HNSCC).
"Marketing authorisation of efti in multiple indications"
"Fully exploit the compelling potential"
"Expansion of clinical settings..and enhance efti value"

This is better but now needs to be converted into action and milestones clearly articulated/documented.